Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K, Gravis G, James ND, Liu G, Matheson D, Murphy L, Oldroyd RE, Parmar MKB, Rogozinska E, Sfumato P, Sweeney CJ, Sydes MR, Tombal B, White IR, Tierney JF; STOPCAP Collaboration.
Vale CL, et al. Among authors: rydzewska lh.
Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9.
Lancet Oncol. 2023.
PMID: 37414011
Free PMC article.